SCHEMBL5089943

SCHEMBL5089943

CCCc1c(O)cc(OC)cc1CC(=O)OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.44
▸ POLB P06746 2/20 0.44
▸ ABL1 P00519 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ RIN1 Q13671 1/20 0.44
▸ CTDSP1 Q9GZU7 1/20 0.44
▸ HMGCR P04035 2/20 0.44
▸ HSP90AB1 P08238 1/20 0.42
▸ PTGES O14684 1/20 0.42
▸ EGFR P00533 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HPGD P15428 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ MTNR1A P48039 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5092345 0.87 POLB (0.60) KDM4EPOLBABL1MAPTRECQL
SCHEMBL2861715 0.75 HSP90AB1 (0.51) KDM4EPOLBHMGCRHSP90AB1EGFR
SCHEMBL21957647 0.74 NFKB1 (0.47) KDM4EPOLBMAPTHSP90AB1HPGD
SCHEMBL5090755 0.74 MTNR1A (0.50) TDP1L3MBTL1ALDH1A1MTNR1AMTNR1B
SCHEMBL6035480 0.73 POLB (0.64) KDM4EPOLBHSP90AB1EGFRL3MBTL1
SCHEMBL30336005 0.73 POLB (0.64) KDM4EPOLBHSP90AB1EGFRL3MBTL1
SCHEMBL4034916 0.73 MTNR1A (0.56) KDM4EPOLBMAPTEGFRHPGD
SCHEMBL4031952 0.73 ALDH1A1 (0.53) KDM4EHMGCRHSP90AB1EGFRHPGD
SCHEMBL7115040 0.73 HMGCR (0.50) HMGCRCYP3A4PTGS2PTPN1
SCHEMBL2862203 0.71 CYP2D6 (0.54) KDM4EPOLBABL1MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348017-B2 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin SHISEIDO CO., LTD. (JP) 2008-03-25 — — US disclosed
EP-1422224-B1 DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN SHISEIDO CO LTD (JP) 2007-12-19 — — EP disclosed
US-20040236111-A1 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin SHISEIDO CO., LTD. (JP) 2004-11-25 — — US disclosed
EP-1422224-A1 DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN Shiseido Co., Ltd. (JP) 2004-05-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236111-A1 Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin MMP1, MMP2, MMP3 KDM4E 1020/4885POLB 1019/4885ABL1 4227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback